Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy.
Tsung-Yi LinJeong A ParkAlan LongHong-Fen GuoNai Kong V CheungPublished in: Journal for immunotherapy of cancer (2022)
BC261 was highly efficient in driving T cell infiltration and tumor ablation. Either as stand-alone therapeutics or for ex vivo armed T cells, this novel anti-STEAP1 T-BsAb BC261 has therapeutic potential.